Larimar Therapeutics (LRMR) Return on Equity (2016 - 2020)
Historic Return on Equity for Larimar Therapeutics (LRMR) over the last 7 years, with Q3 2020 value amounting to 0.1%.
- Larimar Therapeutics' Return on Equity rose 7000.0% to 0.1% in Q3 2020 from the same period last year, while for Sep 2020 it was 0.1%, marking a year-over-year increase of 7000.0%. This contributed to the annual value of 0.98% for FY2019, which is 2700.0% down from last year.
- As of Q3 2020, Larimar Therapeutics' Return on Equity stood at 0.1%, which was up 7000.0% from 0.29% recorded in Q2 2020.
- Over the past 5 years, Larimar Therapeutics' Return on Equity peaked at 0.1% during Q3 2020, and registered a low of 1.54% during Q4 2019.
- In the last 5 years, Larimar Therapeutics' Return on Equity had a median value of 0.62% in 2018 and averaged 0.67%.
- In the last 5 years, Larimar Therapeutics' Return on Equity plummeted by -9200bps in 2019 and then skyrocketed by 7000bps in 2020.
- Over the past 5 years, Larimar Therapeutics' Return on Equity (Quarter) stood at 0.46% in 2016, then plummeted by -36bps to 0.62% in 2017, then grew by 1bps to 0.62% in 2018, then crashed by -148bps to 1.54% in 2019, then surged by 93bps to 0.1% in 2020.
- Its last three reported values are 0.1% in Q3 2020, 0.29% for Q2 2020, and 1.43% during Q1 2020.